XML 31 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration and Licensing Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2018
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Oct. 16, 2018
Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Deferred revenue   $ 40,847,000       $ 47,565,000         $ 40,847,000 $ 47,565,000   $ 750,000
Deferred revenue - current   32,503,000       36,885,000         32,503,000 36,885,000    
Deferred revenue - long term   8,344,000       10,680,000         8,344,000 10,680,000    
Revenue — collaborations and services   15,993,000 $ 14,595,000 $ 15,002,000 $ 17,448,000 $ 16,031,000 $ 4,469,000 $ 3,893,000 $ 3,465,000   63,038,000 27,859,000    
Income Taxes Paid                       240,000    
Commercial product sales                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Revenue — collaborations and services                     25,304,000 17,276,000    
Collaboration and License Agreement | Receptor                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Deferred revenue - current   300,000                 300,000      
Collaboration and License Agreement | United Therapeutics Corporation                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment received                         $ 45,000,000  
Milestone Payment Received                     12,500,000      
Total transaction price   101,400,000                 101,400,000      
Deferred revenue   38,400,000                 38,400,000      
Deferred revenue - current   31,900,000                 31,900,000      
Deferred revenue - long term   6,500,000                 6,500,000      
Collaboration and License Agreement | United Therapeutics Corporation | Maximum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Potential milestone payments to be receive   25,000,000                 25,000,000      
Additional option exercise and development milestone payments to be receive   40,000,000                 40,000,000      
Research Agreement | United Therapeutics Corporation                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment received             $ 10,000,000              
Total transaction price   10,000,000                 10,000,000      
Deferred revenue - current   200,000                 200,000      
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total transaction price   1,000,000                 $ 1,000,000      
Revenue performance obligation, method used                     The revenue for the engineering consulting services was recognized using a ratable method until the obligation was satisfied. The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation.      
Research Agreement | United Therapeutics Corporation | Product Prototype                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Total transaction price   9,000,000                 $ 9,000,000      
Revenue performance obligation, method used                     The revenue for the product prototype is recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation.      
Research Agreement | United Therapeutics Corporation | Maximum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Potential milestone payments to be receive   30,000,000                 $ 30,000,000      
Supply and Distribution Agreement | Commercial product sales | Biomm                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Revenue — collaborations and services                   $ 700,000        
License and Distribution Agreement | Foreign Country | India Tax Authority                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Income Taxes Paid                       $ 200,000    
License and Distribution Agreement | Cipla Ltd                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Deferred revenue   1,900,000                 1,900,000      
Deferred revenue - current   100,000                 100,000      
Deferred revenue - long term   $ 1,800,000                 $ 1,800,000      
Marketing and distribution agreement date 2018-05